Phase 3 COVID-19 Clinical Trials
22 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 22 trials
Recruiting
Phase 3
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
COVID-19 Infection
Pfizer300 enrolled132 locationsNCT07013474
Recruiting
Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Merck Sharp & Dohme LLC3,082 enrolled222 locationsNCT06667700
Recruiting
Phase 3
Immunosuppression and COVID-19 Boosters
COVID-19
Kirby Institute320 enrolled5 locationsNCT05415267
Recruiting
Phase 2Phase 3
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
Post-Acute COVID-19 SyndromeLong COVIDPost-Acute COVID-19
Hellenic Institute for the Study of Sepsis182 enrolled24 locationsNCT05926505
Recruiting
Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
COVID-19
BioNTech SE25,500 enrolled208 locationsNCT07300839
Recruiting
Phase 3
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
COVID-19
Pfizer160 enrolled73 locationsNCT05261139
Recruiting
Phase 2Phase 3
A Study of Apabetalone in Subjects With Long -COVID
Post-Acute COVID-19 Syndrome
Resverlogix Corp200 enrolled3 locationsNCT06590324
Recruiting
Phase 2Phase 3
Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness
COVID-19 Respiratory Infection
Peking Union Medical College Hospital1,096 enrolled1 locationNCT05689034
Recruiting
Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
COVID-19Lower Respiratory Tract InfectionImmunocompromised+1 more
Ansun Biopharma, Inc.274 enrolled67 locationsNCT03808922
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707
Recruiting
Phase 3Phase 4
Intramuscular versus Subcutaneous COVID-19 needle length RCT
COVID-19
Medical Research Institute of New Zealand (MRINZ)400 enrolled1 locationACTRN12624000294550
Completed
Phase 3
Ivermectin to prevent Coronavirus
COVID-19
Monash University1,000 enrolled1 locationACTRN12621001535864
Terminated
Phase 3
Impact of Colchicine To Improve long-COVID-19 or ARDS Outcomes
COVID-19 Respiratory Infection
University of Sydney1,000 enrolled2 locationsACTRN12621000637842
Not Yet Recruiting
Phase 3
A randomized double-blind placebo-controlled trial of oral ivermectin for outpatient treatment of those at high risk for hospitalization due to COVID-19
SARS-CoV-2 (COVID-19),
Neuroscience Trials Australia400 enrolled1 locationACTRN12620000982910
Withdrawn
Phase 3
C-SMART. COVID-19 Prevention and Treatment in Cancer Arm 4: treatment among cancer patients with severe COVID-19 infection.
CancerCOVID-19
Peter MacCallum Cancer Centre72 enrolled5 locationsACTRN12620000844943
Completed
Phase 3
C-SMART. COVID-19 Prevention and Treatment in Cancer. Arm 1 : Prevention in patients not infected with COVID-19.
CancerCOVID-19
Peter MacCallum Cancer Centre1,914 enrolled5 locationsACTRN12620000843954
Withdrawn
Phase 3
C-SMART. COVID-19 Prevention and Treatment in Cancer. Arm 2 : Post-exposure prevention in patients recently exposed to COVID-19
CancerCOVID-19
Peter MacCallum Cancer Centre170 enrolled5 locationsACTRN12620000842965
Completed
Phase 3
C-SMART. COVID-19 Prevention and Treatment in Cancer. Arm 3: treatment among cancer patients with moderate COVID-19 infection.
CancerCOVID-19
Peter MacCallum Cancer Centre126 enrolled5 locationsACTRN12620000841976
Withdrawn
Phase 3
A Placebo-Controlled Study to Evaluate the effect of the recombinant Bacillus Calmette–Guérin (BCG) vaccine VPM1002 on the Incidence or Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Participants in Australia
COVID-19
Accelagen Pty Ltd3,468 enrolled1 locationACTRN12620000707965
Terminated
Phase 3
Randomised clinical trial of interventions for the treatment of COVID-19 in the community setting.
COVID-19
University of Sydney250 enrolled2 locationsACTRN12620000566932